Cosmo Pharmaceuticals said it plans to file an NDA in 2027 for clascoterone 5% topical solution following positive 12-month Phase III data in androgenetic alopecia. In its largest male AGA Phase III program, Cosmo reported statistically significant improvements in Target Area Hair Count for patients with continuous treatment over a full year, alongside a long-term safety profile comparable with vehicle.